The ASCO Genitourinary (ASCO GU) and the Annual ASCO meetings are the leading educational and scientific events for oncologists, urologists, and the cancer team, providing the latest clinical and scientific data from clinical trials and basic and translational research in GU cancer. Thousands of abstracts summarizing state-of-the-art treatment modalities and novel therapies for patients with Prostate Cancer will be presented and it will be critical that educational programing provide learners with not only key data, but interpretation by faculty as to how best to incorporate into clinical practice.
This activity has been designed to meet the educational needs of the interprofessional team, including Medical Oncologists, Urologists, Nurses, Pharmacists as well as other clinicians involved in the management of patients with prostate cancer.
After participating in this educational activity, participants should be better able to:
- Apply recent practice-changing data to inform sequencing decisions and treatment strategies for patients with prostate cancer
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Daniel J. George, MD, faculty for this educational event, is a contracted researcher for Astellas, AstraZeneca, Bayer H/C Pharmaceuticals, BMS, Calithera, Exelixis, Inc, Janssen, Novartis, Pfizer, and Sanofi; and receives consulting fees from Novartis, Astellas, AstraZeneca, AVEO Pharmaceuticals, Bayer Pharmaceuticals, Brown and James Atty, Eisa, Exelixis, Inc, IdeoOncology, Janssen, Medscape Education, Merck Sharp & Dohme, Michael J Hennessey Associates, Myovant Sciences, Inc, Nektar Therapeutics, Pfizer, Propella TX, Sanofi, Seattle Genetics, UroGPO, UroToday WebMD, WilmerHale and Xcures.
Fred Saad, MD, FRCS, faculty for this educational event, is a contracted researcher for Astellas, AstraZeneca, Bayer, Janssen, Myovant, Pfizer, Novartis/AAA, Point, BMS, and Sanofi; and receives consulting fees from Astellas, Astrazeneca, Bayer, Janssen, Myovant, Pfizer, Novartis/AAA, Point, BMS, Tolmar, and Abbvie.
The following planners/reviewers/managers have disclosed:
Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.
William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.
TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.
All the relevant financial relationships for these individuals have been mitigated.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
This activity is supported by independent educational grants from Bayer and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
This activity is FREE to all participants.
During the period 3/3/2023 through 3/3/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:
1. Read the learning objectives and faculty disclosures.
2. Answer a pre-program question.
3. View the program.
4. Complete the post-test with a score of 100%.
5. Complete activity evaluation.
6. Apply for credit and either bank your credits or print your certificate.
For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.